Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5280772
Max Phase: Preclinical
Molecular Formula: C22H25F3N2O4
Molecular Weight: 438.45
Associated Items:
ID: ALA5280772
Max Phase: Preclinical
Molecular Formula: C22H25F3N2O4
Molecular Weight: 438.45
Associated Items:
Canonical SMILES: O=C(CCCCCCNC(=O)C(O)(O)C(F)(F)F)Nc1ccc(-c2ccccc2)cc1
Standard InChI: InChI=1S/C22H25F3N2O4/c23-22(24,25)21(30,31)20(29)26-15-7-2-1-6-10-19(28)27-18-13-11-17(12-14-18)16-8-4-3-5-9-16/h3-5,8-9,11-14,30-31H,1-2,6-7,10,15H2,(H,26,29)(H,27,28)
Standard InChI Key: ALWAFPQKUFSFNP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 438.45 | Molecular Weight (Monoisotopic): 438.1766 | AlogP: 3.60 | #Rotatable Bonds: 10 |
Polar Surface Area: 98.66 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 6.50 | CX Basic pKa: | CX LogP: 3.92 | CX LogD: 2.95 |
Aromatic Rings: 2 | Heavy Atoms: 31 | QED Weighted: 0.34 | Np Likeness Score: -0.75 |
1. Riddhidev B, Endri K, Sabitri L, Kotsull Lauren N, Nishanth K, Dragan I, Mary Kay H P, James S, William T, L M Viranga T.. (2022) Rational design of metabolically stable HDAC inhibitors: An overhaul of trifluoromethyl ketones., 244 [PMID:36244186] [10.1016/j.ejmech.2022.114807] |
Source(1):